Clinical Trials Logo

Clinical Trial Summary

There is no cure to arrest or delay SBMA progression. It is estimated that ~1000 individuals are affected by SBMA in Italy at any given time (prevalence: 1.5/100000) with an annual incidence of 0.19/100000 males. Here, we are going to test the potential of beta2-agonist stimulation on muscle as a therapeutic avenue for SBMA. We have provided pre-clinical evidence that β-agonist stimulation may be a therapeutic strategy for SBMA. Moreover, we have shown that beta2-agonists are effective in improving motor function without relevant adverse events in a small cohort of SBMA patients. To establish safety and efficacy of clenbuterol as a cure for SBMA, we are conducting a multicenter, phase II, randomized, double-blind, parallel-group, single dose, placebo-controlled trial. Indeed, based on our preliminary data, some concerns remain to be addressed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06169046
Study type Interventional
Source University Hospital Padova
Contact Gianni Sorarù, MD
Phone 0498213600
Email gianni.soraru@unipd.it
Status Recruiting
Phase Phase 2
Start date April 13, 2024
Completion date December 31, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT04944940 - Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Recruiting NCT03555578 - Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Completed NCT00303446 - Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA) Phase 2
Recruiting NCT06411912 - A Study of NIDO-361 in Patients With SBMA Phase 2
Completed NCT02156141 - High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy N/A
Completed NCT02024932 - Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy Phase 2
Active, not recruiting NCT05517603 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients Phase 1/Phase 2